LTRNNCMHealthcare·Biotechnology#478 in industry

Lantern Pharma Inc.

Reports in 17d· 2026-05-14

-25.7% · 90d

$2.46

+0.00 (+0.00%)

After-Hours $2.46(+0.00)

News

(1)

March 2026

Mar 30, 20260 months ago8-KHealthcare

Lantern Pharma Inc. — 8-K Filing

LTRNLantern Pharma Inc.

# 🧾 What This Document Is This is a **Form 8-K filing** with an attached press release (Exhibit 99.1). Think of it as a major news bulletin from Lantern Pharma to its investors. It covers their financial results for the final quarter and full year of 2025, but more importantly, it provides a detail

Read summaryView on SEC EDGAR

Key Data

Market Cap$27.7M

Open$2.35

Prev Close$2.46

Day Range$2.35 – $2.55

52W Range$1.11 – $5.74

Volume180,942

P/E (TTM)—

EPS$-1.57

Dividend Yield—

Beta1.75

Price Target$20.00(+713.0%)

Next Earnings2026-05-14(17d)

Analyst Ratings

Strong Buy2 analysts

Buy 2Hold 0Sell 0

About

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Healthcare · Biotechnology

16 employees

www.lanternpharma.com